TriSalus Life Sciences (NASDAQ: TLSI) insider transactions
In the twelve months to 10 November 2026, executives and directors of TriSalus Life Sciences reported 18 open-market sales of 35,160 shares ($139,922) and 12 open-market purchases of 1,162,267 shares ($3.6m), by 10 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 5 October 2026 | Szela Mary T | CEO and President | Shares withheld for tax | −2,693 | $4.38 | 1,074,990 | Form 4 |
| 5 October 2026 | Stevens Jennifer | Chief Regulatory Officer | Open-market sale | −316 | $4.39 | 123,794 | Form 4 |
| 5 October 2026 | Marshak Richard | Chief Commercial Officer | Open-market sale | −325 | $4.39 | 127,994 | Form 4 |
| 5 October 2026 | Cox Bryan F. | Chief of Research | Open-market sale | −296 | $4.39 | 162,805 | Form 4 |
| 1 July 2026 | Patience David | Chief Financial Officer | Shares withheld for tax | −14,650 | $4.46 | 261,107 | Form 4 |
| 30 June 2026 | Marshak Richard | Chief Commercial Officer | Grant or award | +561 | $3.87 | 128,319 | Form 4 |
| 30 June 2026 | Szela Mary T | CEO and President | Grant or award | +3,990 | $3.87 | 1,077,683 | Form 4 |
| 29 June 2026 | Marshall Richard Henry | Chief Medical Officer | Grant or award | +60,000 | — | 90,000 | Form 4 |
| 15 May 2026 | Marshak Richard | Chief Commercial Officer | Open-market sale | −543 | $2.67 | 125,101 | Form 4 |
| 15 May 2026 | Gordon Gary B. | Director | Open-market purchase | +10,000 | $2.46 | 72,510 | Form 4 |
| 15 May 2026 | Patience David | Chief Financial Officer | Open-market purchase | +7,100 | $2.43 | 275,757 | Form 4 |
| 15 May 2026 | Szela Mary T | CEO and President | Open-market purchase | +39,682 | $2.59 | 1,065,215 | Form 4 |
| 15 May 2026 | Stansky Michael P | Director | Open-market purchase | +410,000 | $2.50 | 1,240,722 | Form 4 |
| 15 May 2026 | Stansky Michael P | Director | Open-market purchase | +200,000 | $2.50 | 399,698 | Form 4 |
| 15 May 2026 | Wahlstrom Mats | Director | Open-market purchase | +60,000 | $2.53 | 147,555 | Form 4 |
| 14 May 2026 | Stansky Michael P | Director | Grant or award | +23,501 | — | 810,633 | Form 4 |
| 14 May 2026 | Stansky Michael P | Director | Grant or award | +20,089 | — | 830,722 | Form 4 |
| 14 May 2026 | Valle William | Director | Grant or award | +28,201 | — | 58,688 | Form 4 |
| 14 May 2026 | Valle William | Director | Grant or award | +24,553 | — | 83,241 | Form 4 |
| 14 May 2026 | Matlin David J | Director | Grant or award | +28,201 | — | 1,300,145 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the TriSalus Life Sciences page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.